REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters

Baum, Alina, Ajithdoss, Dharani, Copin, Richard, Zhou, Anbo, Lanza, Kathryn, Negron, Nicole, Ni, Min, Wei, Yi +28 more·2020·Science
DOI 10.1126/science.abe2402

Cited by (524)

Items 101–200 of 524

  1. Risk of rapid evolutionary escape from biomedical interventions targeting SARS-CoV-2 spike protein
    Debra Van Egeren, Alexander Novokhodko, Madison Stoddard, Uyen Tran, Bruce R. Zetter, Michael S. Rogers, Bradley L. Pentelute, Jonathan M. Carlson, Mark S. Hixon, Diane Joseph‐McCarthy et al. · 2021 · PLoS ONE
  2. Extracellular vesicles carry SARS‐CoV‐2 spike protein and serve as decoys for neutralizing antibodies
    Zach Troyer, Najwa Alhusaini, Caroline O. Tabler, Thomas J. Sweet, Karina Inacio Carvalho, Daniela Schlatzer, Lenore L. Carias, Christopher L. King, Kenneth A. Matreyek, John C. Tilton · 2021 · Journal of Extracellular Vesicles
  3. SARS-CoV-2 mutations acquired in mink reduce antibody-mediated neutralization
    Markus Hoffmann, Lu Zhang, Nadine Krüger, Luise Graichen, Hannah Kleine‐Weber, Heike Hofmann-Winkler, Amy Madeleine Kempf, Stefan Nessler, Joachim Riggert, Martin Sebastian Winkler et al. · 2021 · Cell Reports
  4. 501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to bamlanivimab in vitro
    Haolin Liu, Pengcheng Wei, Qianqian Zhang, Zhongzhou Chen, Katja Aviszus, Walter Downing, Shelley W. Peterson, Lyndon Reynoso, Gregory Paul Downey, Stephen K. Frankel et al. · 2021 · mAbs
  5. Similarities and Dissimilarities of COVID-19 and Other Coronavirus Diseases
    To Sing Fung, Ding Xiang Liu · 2021 · Annual Review of Microbiology
  6. Immunology, immunopathogenesis and immunotherapeutics of COVID-19; an overview
    Leila Mohamed Khosroshahi, Mohsen Rokni, Tahmineh Mokhtari, Farshid Noorbakhsh · 2021 · International Immunopharmacology
  7. Decay of Fc-dependent antibody functions after mild to moderate COVID-19
    Wen Shi Lee, Kevin John Selva, Samantha K. Davis, Bruce D. Wines, Arnold Reynaldi, Robyn Esterbauer, Hannah G. Kelly, Ebene R. Haycroft, Hyon‐Xhi Tan, Jennifer A. Juno et al. · 2021 · Cell Reports Medicine
  8. Computational prediction of the effect of amino acid changes on the binding affinity between SARS-CoV-2 spike RBD and human ACE2
    Chen Chen, Veda Sheersh Boorla, Deepro Banerjee, Ratul Chowdhury, Victoria S. Cavener, Ruth Helmus Nissly, Abhinay Gontu, Nina R. Boyle, Kurt J. Vandegrift, Meera Surendran Nair et al. · 2021 · Proceedings of the National Academy of Sciences
  9. Long-term persistence of RBD+ memory B cells encoding neutralizing antibodies in SARS-CoV-2 infection
    Abayasingam, Arunasingam, Balachandran, Harikrishnan, Agapiou, David, Hammoud, Mohamed, Rodrigo, Chaturaka, Keoshkerian, Elizabeth, Li, Hui, Brasher, Nicholas A., Christ, Daniel, Rouet, Romain et al. · 2021 · Cell Reports Medicine
  10. COVID-19—Lessons Learned and Questions Remaining
    Ferric C. Fang, Constance Ann Benson, Carlos del Rı́o, Kathryn M. Edwards, Vance G. Fowler, David N. Fredricks, Ajit P. Limaye, Barbara E. Murray, Susanna Naggie, Peter G. Pappas et al. · 2020 · Clinical Infectious Diseases
  11. An engineered bispecific human monoclonal antibody against SARS-CoV-2
    Zhaohui Li, Shihua Li, Gen Zhang, Weiyu Peng, Zhen Chang, Xue Zhang, Zheng Fan, Yan Chai, Feiran Wang, Xin Zhao et al. · 2022 · Nature Immunology
  12. Tackling COVID-19 with neutralizing monoclonal antibodies
    Corti, Davide, Purcell, Lisa A., Snell, Gyorgy, Veesler, David · 2021 · Cell
  13. Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein
    Suryadevara, Naveenchandra, Shrihari, Swathi, Gilchuk, Pavlo, VanBlargan, Laura A., Binshtein, Elad, Zost, Seth J., Nargi, Rachel S., Sutton, Rachel E., Winkler, Emma S., Chen, Elaine C. et al. · 2021
  14. Therapeutic activity of an inhaled potent SARS-CoV-2 neutralizing human monoclonal antibody in hamsters
    Michael S. Piepenbrink, Jun‐Gyu Park, Fatai S. Oladunni, Ashlesha A. Deshpande, Madhubanti Basu, Sanghita Sarkar, Andreas Loos, Jennifer C. Woo, Phillip M. Lovalenti, Derek D. Sloan et al. · 2021 · Cell Reports Medicine
  15. Understanding the Co-Epidemic of Obesity and COVID-19: Current Evidence, Comparison with Previous Epidemics, Mechanisms, and Preventive and Therapeutic Perspectives
    Μaria Dalamaga, Gerasimos Socrates Christodoulatos, Ιrene Karampela, Natalia G. Vallianou, Caroline Margaret Apovian · 2021 · Current Obesity Reports
  16. SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies
    Wenping Gong, Seppo Parkkila, Xueqiong Wu, Ashok Aspatwar · 2022 · International Reviews of Immunology
  17. Identification of a therapeutic interfering particle—A single-dose SARS-CoV-2 antiviral intervention with a high barrier to resistance
    S. Chaturvedi, Gustavo Vasen, M. Pablo, Xinyue Chen, N. Beutler, Arjun J. Kumar, Elizabeth J. Tanner, S. Illouz, Donna Rahgoshay, John C. Burnett et al. · 2021 · Cell
  18. SARS-CoV-2 RNA reverse-transcribed and integrated into the human genome
    Liguo Zhang, Alexsia L. Richards, Andrew S. Khalil, Emile Wogram, Haiting Ma, Richard A. Young, Rudolf Jaenisch · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
  19. Review: Insights on Current FDA-Approved Monoclonal Antibodies Against Ebola Virus Infection
    Olivier Tshiani Mbaya, Philippe Mukumbayi, Sabue Mulangu · 2021 · Frontiers in Immunology
  20. Genetic and structural basis for recognition of SARS-CoV-2 spike protein by a two-antibody cocktail
    Dong, Jinhui, Zost, Seth J., Greaney, Allison J., Starr, Tyler N., Dingens, Adam S., Chen, Elaine C., Chen, Rita E., Case, James Brett, Sutton, Rachel E., Gilchuk, Pavlo et al. · 2021
  21. Design and proof of concept for targeted phage-based COVID-19 vaccination strategies with a streamlined cold-free supply chain
    Daniela I. Staquicini, Fenny H. F. Tang, Christopher Markosian, Virginia J. Yao, Fernanda I. Staquicini, Esteban Dodero‐Rojas, Vinícius G. Contessoto, Deodate Davis, Paul O’Brien, Nazia Habib et al. · 2021 · Proceedings of the National Academy of Sciences
  22. Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates
    J. Francica, Barbara Flynn, K. Foulds, Amy T. Noe, Anne P. Werner, Ian N. Moore, M. Gagne, T. Johnston, C. Tucker, Rachel L. Davis et al. · 2021 · Science Translational Medicine
  23. Animal models for SARS-CoV-2
    Chung-Young Lee, Anice C. Lowen · 2021 · Current Opinion in Virology
  24. Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus Compounds
    Philip L. Tzou, Kaiming Tao, Janin Nouhin, Soo‐Yon Rhee, Benjamin D Hu, Shruti Pai, Neil T. Parkin, Robert W. Shafer · 2020 · Viruses
  25. An NTD supersite of attack
    Shee‐Mei Lok · 2021 · Cell Host & Microbe
  26. Neutralization of SARS‐CoV‐2 requires antibodies against conformational receptor‐binding domain epitopes
    Pia Gattinger, Katarzyna Niespodziana, Karin Stiasny, Sabina Sahanic, Inna Tulaeva, Kristina Borochova, Yulia Dorofeeva, Thomas Schlederer, Thomas Sonnweber, Gerhard Höfer et al. · 2021 · Allergy
  27. Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain
    Adam K. Wheatley, Phillip Pymm, Robyn Esterbauer, Melanie H. Dietrich, Wen Shi Lee, Damien R. Drew, Hannah G. Kelly, Li‐Jin Chan, Francesca L. Mordant, Katrina A. Black et al. · 2021 · Cell Reports
  28. Co-infection of SARS-CoV-2 and influenza virus causes more severe and prolonged pneumonia in hamsters
    Takaaki Kinoshita, Kenichi Watanabe, Yasuteru Sakurai, Kodai Nishi, Rokusuke Yoshikawa, Jiro Yasuda · 2021 · Scientific Reports
  29. A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2 variants
    Yanyun Du, Rui Shi, Ying Zhang, Xiaomin Duan, Li Li, Jing Zhang, Fengze Wang, Ruixue Zhang, Hao Shen, Yue Wang et al. · 2021 · Nature Communications
  30. Structures of Omicron spike complexes and implications for neutralizing antibody development
    Hangtian Guo, Yan Gao, Tinghan Li, Tingting Li, Yuchi Lu, Le Zheng, Yue Liu, Tingting Yang, Feiyang Luo, Shuyi Song et al. · 2022 · Cell Reports
  31. Durability of Immunity to SARS-CoV-2 and Other Respiratory Viruses
    Matthew K. Siggins, Ryan S. Thwaites, Peter Openshaw · 2021 · Trends in Microbiology
  32. Efficacy of GC-376 against SARS-CoV-2 virus infection in the K18 hACE2 transgenic mouse model
    C. Joaquín Cáceres, Stivalis Cardenas Garcia, Silvia Carnaccini, Brittany Seibert, Daniela S. Rajão, Jun Wang, Daniel Roberto Perez · 2021 · Scientific Reports
  33. CRISPR systems: Novel approaches for detection and combating COVID-19
    Fatemeh Safari, Mohammad Afarid, Banafsheh Rastegari, Afshin Borhani‐Haghighi, Mazyar Barekati‐Mowahed, Abbas Behzad‐Behbahani · 2021 · Virus Research
  34. Potential SARS-CoV-2 Immune Correlates of Protection in Infection and Vaccine Immunization
    Yongjun Sui, Yonas Bekele, Jay A. Berzofsky · 2021 · Pathogens
  35. A SARS-CoV-2 antibody broadly neutralizes SARS-related coronaviruses and variants by coordinated recognition of a virus-vulnerable site
    Taishi Onodera, Shunsuke Kita, Yu Adachi, Saya Moriyama, Akihiko Sato, Takao Nomura, Shuhei Sakakibara, Takeshi Inoue, Takashi Tadokoro, Yuki Anraku et al. · 2021 · Immunity
  36. Success of prophylactic antiviral therapy for SARS-CoV-2: Predicted critical efficacies and impact of different drug-specific mechanisms of action
    Peter Czuppon, Florence Débarre, António Gonçalves, Olivier Tenaillon, Alan S. Perelson, Jérémie Guedj, François Blanquart · 2021 · PLoS Computational Biology
  37. SARS-CoV-2: Targeted managements and vaccine development
    Moiz Bakhiet, Sébastien Taurin · 2020 · Cytokine & Growth Factor Reviews
  38. Development and application of therapeutic antibodies against COVID-19
    Lin-jin Ning, H. B. Abagna, Qianhu Jiang, Siqi Liu, Jian Huang · 2021 · International Journal on Biological Sciences
  39. In vitro evaluation of therapeutic antibodies against a SARS-CoV-2 Omicron B.1.1.529 isolate
    Franck Touret, Cécile Baronti, Hawa Sophia Bouzidi, Xavier Nicolas de Lamballerie · 2022 · Scientific Reports
  40. The temperature-dependent conformational ensemble of SARS-CoV-2 main protease (M pro )
    Ali Ebrahim, Blake T. Riley, Desigan Kumaran, Babak Andi, Martin R. Fuchs, Sean M. McSweeney, D.A. Keedy · 2022 · IUCrJ
  41. Intranasal Administration of a Monoclonal Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection
    Sandro Halwe, Alexandra Kupke, Kanika Vanshylla, Falk Liberta, Henning Gruell, Matthias Zehner, Cornelius Rohde, Verena Krähling, Michelle Gellhorn Serra, Christoph Kreer et al. · 2021 · Viruses
  42. The impact of neutralizing monoclonal antibodies on the outcomes of COVID‐19 outpatients: A systematic review and meta‐analysis of randomized controlled trials
    Wei‐Ting Lin, Shun‐Hsing Hung, Chih‐Cheng Lai, Cheng‐Yi Wang, Chao‐Hsien Chen · 2022 · Journal of Medical Virology
  43. Post-exposure protection of SARS-CoV-2 lethal infected K18-hACE2 transgenic mice by neutralizing human monoclonal antibody
    Ronit Rosenfeld, Tal Noy-Porat, Adva Mechaly, Efi Makdasi, Yinon Levy, Ron Alcalay, Reut Falach, Moshe Aftalion, Eyal Epstein, David Gur et al. · 2021 · Nature Communications
  44. A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants
    Denise Haslwanter, M. Eugenia Dieterle, Anna Z. Wec, Cecilia M. O’Brien, Mrunal Sakharkar, Catalina Florez, Karen Tong, C. Garrett Rappazzo, Gorka Lasso, Olivia Vergnolle et al. · 2021 · mBio
  45. Antibody-dependent enhancement (ADE) of SARS-CoV-2 pseudoviral infection requires FcγRIIB and virus-antibody complex with bivalent interaction
    Shuang Wang, Junchao Wang, Xiaojuan Yu, Wen Jiang, Shuo Chen, Rongjuan Wang, Mingzhu Wang, Shasha Jiao, Wenbo Wang, Wenbo Wang et al. · 2022 · Communications Biology
  46. SARS-CoV-2 viral dynamics in non-human primates
    Antonio Gonçalves, P. Maisonnasse, F. Donati, Mélanie Albert, S. Behillil, V. Contreras, Thibaut Naninck, R. Marlin, C. Solas, A. Pizzorno et al. · 2021 · PLoS Comput. Biol.
  47. Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis
    Jennifer M. Zupancic, Alec A. Desai, John S. Schardt, Ghasidit Pornnoppadol, Emily K. Makowski, Matthew D. Smith, Andrew A. Kennedy, Mayara Garcia de Mattos Barbosa, Marília Cascalho, Thomas M. Lanigan et al. · 2021 · Cell chemical biology
  48. COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models
    Pauline Maisonnasse, Yoann Aldon, Aurélien Marc, Romain Marlin, Nathalie Dereuddre‐Bosquet, Natalia A. Kuzmina, Alec W. Freyn, Jonne L. Snitselaar, António Gonçalves, Tom G. Caniels et al. · 2021 · Nature Communications
  49. Sex Disparities and Neutralizing-Antibody Durability to SARS-CoV-2 Infection in Convalescent Individuals
    A. Markmann, Natasa Giallourou, D. Bhowmik, Y. Hou, A. Lerner, David R. Martinez, L. Premkumar, H. Root, D. van Duin, S. Napravnik et al. · 2021 · Msphere
  50. On the road to ending the COVID-19 pandemic: Are we there yet?
    J. Case, Emma S. Winkler, J. Errico, Michael S. Diamond · 2021 · Virology
  51. Myeloid cell interferon responses correlate with clearance of SARS-CoV-2
    D. Singh, E. Aladyeva, Shibali Das, Bindu Singh, E. Esaulova, A. Swain, Mushtaq Ahmed, Journey Cole, Chivonne Moodley, S. Mehra et al. · 2022 · Nature Communications
  52. Mechanisms of Lung Injury Induced by SARS-CoV-2 Infection
    Samsara W. Upadhya, Jalees Rehman, Asrar B. Malik, Shuibing Chen · 2021 · Physiology
  53. What are the current anti-COVID-19 drugs? From traditional to smart molecular mechanisms
    Sawsan Aboul‐Fotouh, Ahmed N. Mahmoud, Esraa M. Elnahas, Mohamed Z. Habib, Sahar M. Abdelraouf · 2023 · Virology Journal
  54. Molecular probes of spike ectodomain and its subdomains for SARS-CoV-2 variants, Alpha through Omicron
    I‐Ting Teng, Alexandra F. Nazzari, Misook Choe, Tracy W. B. Liu, Matheus Oliveira de Souza, Yuliya I. Petrova, Yaroslav Tsybovsky, Shuishu Wang, Baoshan Zhang, Mykhaylo V Artamonov et al. · 2022 · PLoS ONE
  55. Neutralizing monoclonal antibodies for COVID-19 treatment and prevention
    J. Jaworski · 2020 · Biomedical Journal
  56. Intranasal gene therapy to prevent infection by SARS-CoV-2 variants
    Joshua J. Sims, Jenny A. Greig, Kristofer T. Michalson, Sharon Lian, R. Alexander Martino, Rosemary Meggersee, Kevin B. Turner, Kalyani Nambiar, Cecilia Dyer, Christian J. Hinderer et al. · 2021 · PLoS Pathogens
  57. Safety, Virologic Efficacy, and Pharmacokinetics of CT-P59, a Neutralizing Monoclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Protein: Two Randomized, Placebo-Controlled, Phase I Studies in Healthy Individuals and Patients With Mild SARS-CoV-2 Infection
    Jin Yong Kim, Young Rock Jang, Jang Hee Hong, Jin Gyu Jung, Jae‐Hyeong Park, Adrian Streinu‐Cercel, Anca Streinu-Cercel, Oana Săndulescu, Sang Joon Lee, Sung Hyun Kim et al. · 2021 · Clinical Therapeutics
  58. SARS-CoV-2 resistance to monoclonal antibodies and small-molecule drugs
    Sho Iketani, David D. Ho · 2024 · Cell chemical biology
  59. Engineering ACE2 decoy receptors to combat viral escapability
    Takao Arimori, Nariko Ikemura, Toru Okamoto, Junichi Takagi, Daron M. Standley, Atsushi Hoshino · 2022 · Trends in Pharmacological Sciences
  60. SARS-CoV-2 in animals: From potential hosts to animal models
    Anna Michelitsch, K. Wernike, Lorenz Ulrich, T. Mettenleiter, M. Beer · 2021 · Advances in Virus Research
  61. SARS-CoV-2 Neutralizing Human Antibodies Protect Against Lower Respiratory Tract Disease in a Hamster Model
    Bart L. Haagmans, Danny Noack, Nisreen M.A. Okba, Wentao Li, Chunyan Wang, Theo M. Bestebroer, Rory D. de Vries, Sander Herfst, Dennis de Meulder, Elwin P. Verveer et al. · 2021 · The Journal of Infectious Diseases
  62. Overview of Targets and Potential Drugs of SARS-CoV-2 According to the Viral Replication
    Yi Zhang, Liang V. Tang · 2020 · Journal of Proteome Research
  63. The Immunopathology of COVID-19 and the Cannabis Paradigm
    Nicole Paland, Antonina Pechkovsky, Miran Aswad, Haya Hamza, Tania Popov, Eduardo Shahar, Igal Louria‐Hayon · 2021 · Frontiers in Immunology
  64. Inhalation of ACE2-expressing lung exosomes provides prophylactic protection against SARS-CoV-2
    Zhenzhen Wang, Shiqi Hu, Kristen D. Popowski, Shuo Liu, Dashuai Zhu, Xuan Mei, Junlang Li, Yilan Hu, Phuong‐Uyen Dinh, Xiaojie Wang et al. · 2024 · Nature Communications
  65. COVID-19 therapeutics
    Daniele Focosi, Massimo Franchini, Fabrizio Maggi, Shmuel Shoham · 2024 · Clinical Microbiology Reviews
  66. Monoclonal antibody therapies in the management of SARS-CoV-2 infection
    Enrique Míguez Rey, Dasom Choi, Seungmin Kim, Sangwook Yoon, Oana Săndulescu · 2022 · Expert Opinion on Investigational Drugs
  67. Keep out! SARS-CoV-2 entry inhibitors: their role and utility as COVID-19 therapeutics
    Lennox Chitsike, Penelope J. Duerksen-Hughes · 2021 · Virology Journal
  68. SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19
    Caroline Hirsch, Yun Soo Park, Vanessa Piechotta, Khai Li Chai, Lise J Estcourt, Ina Monsef, Susanne Salomon, Erica M. Wood, Cynthia So‐Osman, Zoe McQuilten et al. · 2022 · Cochrane Database of Systematic Reviews
  69. Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including Omicron
    Huan Ma, Xinghai Zhang, Peiyi Zheng, Peter H. Dube, Weihong Zeng, Shaohong Chen, Qingyu Cheng, Yunru Yang, Yan Wu, Junhui Zhou et al. · 2022 · Cell Research
  70. Engineered Multivalent Nanobodies Potently and Broadly Neutralize SARS‐CoV‐2 Variants
    Jennifer M. Zupancic, John S. Schardt, Alec A. Desai, Emily K. Makowski, Matthew D. Smith, Ghasidit Pornnoppadol, Mayara Garcia de Mattos Barbosa, Marília Cascalho, Thomas M. Lanigan, Peter M. Tessier · 2021 · Advanced Therapeutics
  71. Report of the National Institutes of Health SARS-CoV-2 Antiviral Therapeutics Summit
    Matthew D. Hall, James Melvin Anderson, Annaliesa S. Anderson, David A. Baker, James E. Bradner, Kyle R. Brimacombe, Elizabeth A. Campbell, Kizzmekia S. Corbett, Kara L. Carter, Sara R. Cherry et al. · 2021 · The Journal of Infectious Diseases
  72. Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?
    Ligong Lu, Hui Zhang, Meixiao Zhan, Jun Jiang, Hua Yin, Danielle J. Dauphars, Shi-You Li, Yong Li, You-Wen He · 2020 · Science China Life Sciences
  73. Insights into neutralizing antibody responses in individuals exposed to SARS-CoV-2 in Chile
    Carolina Beltrán-Pavez, Sebastián Riquelme-Barrios, Aarón Oyarzún-Arrau, Aracelly Gaete-Argel, Roxana González‐Stegmaier, Karina Cereceda, Adam Aguirre, Dante Travisany, Ricardo Palma-Véjares, Gonzalo P. Barriga et al. · 2021 · Science Advances
  74. A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants
    Zhen-Lin Yang, Yulu Wang, Yu-jia Jin, Yuan-Fei Zhu, Yan-Ling Wu, Cheng Li, Yu Kong, Wen-Ping Song, Xiaolong Tian, Wuqiang Zhan et al. · 2021 · Signal Transduction and Targeted Therapy
  75. SARS-CoV-2 immunity in animal models
    Zhaoming Chen, Yaochang Yuan, Qingtao Hu, Ai-Ru Zhu, Fenghua Chen, Shu Li, Xin Guan, Chao Lv, Tian Tang, Yi-Yun He et al. · 2024 · Cellular & Molecular Immunology
  76. Treatment and prevention strategies for the COVID 19 pandemic: A review of immunotherapeutic approaches for neutralizing SARS-CoV-2
    Pravas Kumar Baral, Jiang Yin, Michael N.G. James · 2021 · International Journal of Biological Macromolecules
  77. T follicular helper cells in the humoral immune response to SARS-CoV-2 infection and vaccination
    Marios Koutsakos, Wen Shi Lee, Adam K Wheatley, Stephen J Kent, Jennifer A. Juno · 2021 · Journal of Leukocyte Biology
  78. Structure-based neutralizing mechanisms for SARS-CoV-2 antibodies
    Qingrui Huang, Xiaonan Han, Jinghua Yan · 2022 · Emerging Microbes & Infections
  79. Therapeutic antibodies, targeting the SARS-CoV-2 spike N-terminal domain, protect lethally infected K18-hACE2 mice
    Tal Noy-Porat, Adva Mechaly, Yinon Levy, Efi Makdasi, Ron Alcalay, David Gur, Moshe Aftalion, Reut Falach, Shani Leviatan Ben‐Arye, Shirley Lazar et al. · 2021 · iScience
  80. An ultrapotent pan-β-coronavirus lineage B (β-CoV-B) neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope
    Zezhong Liu, Wei Xu, Zhenguo Chen, Wangjun Fu, Wuqiang Zhan, Yidan Gao, Jie Zhou, Yunjiao Zhou, Jianbo Wu, Qian Wang et al. · 2021 · Protein & Cell
  81. Enhanced SARS-CoV-2 Neutralization by Secretory IgA in vitro
    Zijun Wang, Julio C. C. Lorenzi, Frauke Muecksch, Shlomo Finkin, Charlotte Viant, Christian Gaebler, Melissa Cipolla, Hans-Heinrich Hoffmann, Thiago Y. Oliveira, Deena A. Oren et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
  82. Mechanisms of Dysregulated Humoral and Cellular Immunity by SARS-CoV-2
    N. Taefehshokr, Sina Taefehshokr, B. Heit · 2020 · Pathogens
  83. Vaccination with SARS-CoV-2 Spike Protein and AS03 Adjuvant Induces Rapid Anamnestic Antibodies in the Lung and Protects Against Virus Challenge in Nonhuman Primates
    J. Francica, Barbara Flynn, K. Foulds, Amy T. Noe, Anne P. Werner, Ian N. Moore, M. Gagne, T. Johnston, C. Tucker, Rachel L. Davis et al. · 2021 · bioRxiv
  84. Convalescent plasma therapy in COVID-19: Unravelling the data using the principles of antibody therapy
    Arturo Casadevall, Michael J. Joyner, Liise‐anne Pirofski, Jonathon W. Senefeld, Shmuel Shoham, David J. Sullivan, Nigel Paneth, Daniele Focosi · 2023 · Expert Review of Respiratory Medicine
  85. Single domain shark VNAR antibodies neutralize SARS‐CoV‐2 infection in vitro
    Aziz Gauhar, Cyril V. Privezentzev, Mykhaylo Demydchuk, Tanja Gerlza, Julia Rieger, Andreas J. Kungl, Frank S. Walsh, Julia Lynn Rutkowski, Paweł Stocki · 2021 · The FASEB Journal
  86. Mini-review: The market growth of diagnostic and therapeutic monoclonal antibodies – SARS CoV-2 as an example
    Yasmine S. El Abd, Ashraf Abdou Tabll, Robert Smolić, Martina Smolić · 2021 · Human Antibodies
  87. Intricate confrontation: Research progress and application potential of TRIM family proteins in tumor immune escape
    Junjie Gu, Jingyi Chen, Shuaixi Xiang, Xikun Zhou, Jing Li · 2023 · Journal of Advanced Research
  88. An intranasal nanoparticle STING agonist protects against respiratory viruses in animal models
    Ankita Leekha, Arash Saeedi, Monish Kumar, K M Samiur Rahman Sefat, Melisa A. Martinez-Paniagua, Hui Meng, Mohsen Fathi, Rohan SUDHIR Kulkarni, Kate Reichel, Sujit Biswas et al. · 2024 · Nature Communications
  89. A single dose of replication-competent VSV-vectored vaccine expressing SARS-CoV-2 S1 protects against virus replication in a hamster model of severe COVID-19
    Delphine C. Malherbe, Drishya Kurup, Christoph Wirblich, Adam J. Ronk, Chad E. Mire, Natalia A. Kuzmina, Noor Fathima Shaik, Sivakumar Periasamy, Matthew A. Hyde, Julie M. Williams et al. · 2021 · npj Vaccines
  90. The Lambda variant of SARS-CoV-2 has a better chance than the Delta variant to escape vaccines
    Haolin Liu, Pengcheng Wei, Qianqian Zhang, Katja Aviszus, Jared Linderberger, John Jeongseok Yang, Junfeng Liu, Zhongzhou Chen, Hassan Waheed, Lyndon Reynoso et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  91. An Engineered Receptor-Binding Domain Improves the Immunogenicity of Multivalent SARS-CoV-2 Vaccines
    Yan Guo, Wenhui He, H. Mou, Lizhou Zhang, Jing Chang, Shoujiao Peng, Amrita Ojha, Rubens Tavora, M. Parcells, G. Luo et al. · 2021 · mBio
  92. Highly potent anti-SARS-CoV-2 multivalent DARPin therapeutic candidates
    Marcel Walser, Sylvia Rothenberger, Daniel L. Hurdiss, Anja Schlegel, Valérie Calabro, Simon Fontaine, Denis Villemagne, Maria Paladino, Tanja Hospodarsch, Alexandra Neculcea et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
  93. What do we know about the antibody responses to SARS-CoV-2?
    Francisco Alejandro Lagunas‐Rangel, Venice Chávez‐Valencia · 2021 · Immunobiology
  94. Humoral Immunity against SARS-CoV-2 and the Impact on COVID-19 Pathogenesis
    Eun-Jin Lee, Ji Eun Oh · 2021 · Molecules and Cells
  95. Animal models of SARS-CoV-2 and COVID-19 for the development of prophylactic and therapeutic interventions
    Marcel Renn, Eva Bartok, Thomas Zillinger, Gunther Hartmann, Rayk Behrendt · 2021 · Pharmacology & Therapeutics
  96. Progression and Resolution of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Golden Syrian Hamsters
    Kathleen R. Mulka, S. Beck, Clarisse V. Solis, Andrew L. Johanson, S. Queen, Megan E. McCarron, M. Richardson, R. Zhou, Paula Marinho, Anne Jedlicka et al. · 2021 · American Journal of Pathology
  97. The role and uses of antibodies in COVID-19 infections: a living review
    David Oliver Scourfield, Sophie G. Reed, Max N. Quastel, Jennifer Alderson, Valentina M T Bart, Alicia Teijeira Crespo, Ruth E. Jones, Ellie Pring, Felix Clemens Richter, David Ahern et al. · 2021 · Oxford Open Immunology
  98. Clinical Management of COVID-19: A Review of Pharmacological Treatment Options
    Ashli Heustess, Melissa Allard, Dorothea K. Thompson, Pius S. Fasinu · 2021 · Pharmaceuticals
  99. COVID-19 Research: Lessons from Non-Human Primate Models
    Laure Albrecht, Elodie Bishop, Basile Jay, Blaise Lafoux, Marie Minoves, Caroline Passaes · 2021 · Vaccines
  100. UK B.1.1.7 (Alpha) variant exhibits increased respiratory replication and shedding in nonhuman primates
    Kyle Rosenke, Friederike Feldmann, Atsushi Okumura, Frederick Hansen, Tsing-Lee Tang-Huau, Kimberly D. Meade-White, Benjamin Kaza, Julie A. Callison, Matthew C. Lewis, Brian J. Smith et al. · 2021 · Emerging Microbes & Infections